ClinicalTrials.gg
CompletedNCT00297817Updated Dec 1, 2016

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

A Phase 2 interventional study of serogroup B meningococcal vaccine and serogroup B meningococcal vaccine in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 8 sites in United States. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-01.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
11 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.

Enrollment
14th of 21
203 · median 508
Started
2006
the only one that year
Phase 2
7 of 21
1 open now
Registered
1st of 21
by date
Lead sponsor
10 of 21
Novartis Vaccines

Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 14th largest by enrollment, is the only one that started in 2006, is one of 7 in phase 2, and was the 1st registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 11 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing 4CMenB vaccine in Meningococcal Infections, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.

03

Conditions studied

  • Meningococcal Disease

Keywords

  • Meningococcal Disease; Meningococcal Meningitis; Vaccine
04

Who can participate

Ages eligible
11 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Adolescents between and including 11-18 years of age, who provide written .

Exclusion criteria

Exclusion Criteria:

  • Previous or suspected disease caused by N. meningitidis; or previous immunization with a serogroup B meningococcal vaccine; Any acute, chronic or progressive disease.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Arm 1: rMenB

    Biological: serogroup B meningococcal vaccine

  • Experimental
    Arm 2: rMenB + OMV

    Biological: serogroup B meningococcal vaccine

  • Placebo comparator
    Arm 3: Placebo

    Biological: serogroup B meningococcal vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Safety, tolerability and immunogenicity as measured by serum bactericidal activity of the two vaccines in healthy adolescents

    Time frame: 1 month after completion of immunization schedule

Secondary outcomes

  1. Safety, tolerability and immunogenicity as measured by serum bactericidal activity of the two vaccines in healthy adolescents

    Time frame: 6 months after completion of immunization schedule

07

Study locations

8 sites
  • Encinitas, California 92024, United States
  • Atlanta, Georgia 30322, United States
  • St. Louis, Missouri 63110, United States
  • Cleveland, Ohio 44118, United States
  • Galveston, Texas 77555, United States
  • Layton, Utah 84123, United States
  • Salt Lake City, Utah 84121, United States
  • Seattle, Washington 98101, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Apr 2007 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2006
First posted
Mar 1, 2006
Start
Feb 2006
Primary completionActual
Apr 2007
CompletionActual
Apr 2007
Last update
Dec 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00297817
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Mar 1, 2006
Start date
Feb 2006
Primary completion
Apr 2007
Completion
Apr 2007
Last update
Dec 1, 2016

Study contacts

Novartis Vaccines - Drug Information Services
study chair · Novartis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 4CMenB vaccine

Start the discussion